Inclusion Criteria:  Males between the ages of 8-50 years old with a clinical diagnosis of XLRP with a confirmed RPGR mutation who also meet the other requirements of the study. Have at least one documented pathogenic or likely pathogenic variant in the RPGR gene within exons 1-14 and/or ORF15 Have a BCVA no better than 75 letters (20/32) and no worse than 35 letters (20/200) in the study eye based on an Early Treatment of Diabetic Retinopathy Study (ETDRS) chart at each screening visit  Exclusion Criteria:  - Have other known retinal disease mutations or previously received an AAV gene therapy product, as well as being unable or unwilling to meet the requirements of the study.